美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

OMNIAB INC C/WTS (TO PUR COM)

0.0900

0.0000

成交量：- -

成交額：- -

市值：- -

市盈率：-0.15

高：0.0900

開：0.0900

低：0.0900

收：0.0900

52周最高：0.4074

52周最低：0.0751

股本：- -

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.5905

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

OMNIAB INC C/WTS (TO PUR COM)

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.omniab.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

OmniAb, Inc.於2015年12月14日根據特拉華州法律註冊成立。OmniAb的發現平台為製藥行業合作夥伴提供了獲取各種抗體庫和高通量篩選技術的途徑，從而能夠發現下一代療法。OmniAb平台的核心是他們專有的轉基因動物的Biological Intelligence（BI），包括OmniRat、OmniChicken和OmniMouse，這些動物經過基因改造，產生具有人類序列的抗體，以促進人類治療候選藥物的開發。OmniFlic（轉基因大鼠）和OmniClic（轉基因雞）通過一種常見的輕鏈方法滿足了行業對雙特異性抗體應用的需求，而OmniTaur具有牛抗體對複雜靶點的獨特結構屬性。以離子通道和運輸機為重點的既定核心能力進一步使其技術具有差異性，並在新興目標類別中創造了機會。OmniAb抗體已被用於多種模式，包括雙特異性抗體、抗體-藥物偶聯物等。OmniAb技術套件涵蓋從BI驅動的庫生成到尖端抗體發現和優化，為全球製藥行業日益增長的發現需求提供了一種高效且可定製的端到端解決方案。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OABIW/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OABIW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OABIW\",,,,,undefined,":{"symbol":"OABIW","market":"US","secType":"STK","nameCN":"OMNIAB INC C/WTS (TO PUR COM)","latestPrice":0.09,"timestamp":1774641600000,"preClose":0.09,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":-0.5905,"marketStatus":"休市中","change":0,"latestTime":"03-27 16:00:00 EDT","open":0.09,"high":0.09,"low":0.09,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.5905,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.09,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OABIW\",,,,,undefined,":{"symbol":"OABIW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0.09,"amplitude":0,"preClose":0.09,"low":0.09,"week52Low":0.0751,"pbRate":"--","week52High":0.4074,"institutionHeld":0,"latestPrice":0.09,"eps":-0.5905,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.5905,"open":0.09,"prevYearClose":0.1199,"prevWeekClose":0.098,"prevMonthClose":0.0897,"prevQuarterClose":0.1199,"fiveDayClose":0.098,"twentyDayClose":0.0897,"sixtyDayClose":0.1199},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OABIW\",params:#limit:5,,,undefined,":[{"date":"2026-03-04","symbol":"OABIW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772658000000,"name":null,"time":"盤後","dateTimestamp":1772600400000,"actualEps":null},{"date":"2025-11-04","symbol":"OABIW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1762290000000,"name":null,"time":"盤後","dateTimestamp":1762232400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OABIW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OABIW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.omniab.com","stockEarnings":[{"period":"1week","weight":-0.0816},{"period":"1month","weight":0.0033},{"period":"3month","weight":-0.2494},{"period":"6month","weight":-0.3976},{"period":"1year","weight":-0.71},{"period":"ytd","weight":-0.2494}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"OmniAb, Inc.於2015年12月14日根據特拉華州法律註冊成立。OmniAb的發現平台為製藥行業合作夥伴提供了獲取各種抗體庫和高通量篩選技術的途徑，從而能夠發現下一代療法。OmniAb平台的核心是他們專有的轉基因動物的Biological Intelligence（BI），包括OmniRat、OmniChicken和OmniMouse，這些動物經過基因改造，產生具有人類序列的抗體，以促進人類治療候選藥物的開發。OmniFlic（轉基因大鼠）和OmniClic（轉基因雞）通過一種常見的輕鏈方法滿足了行業對雙特異性抗體應用的需求，而OmniTaur具有牛抗體對複雜靶點的獨特結構屬性。以離子通道和運輸機為重點的既定核心能力進一步使其技術具有差異性，並在新興目標類別中創造了機會。OmniAb抗體已被用於多種模式，包括雙特異性抗體、抗體-藥物偶聯物等。OmniAb技術套件涵蓋從BI驅動的庫生成到尖端抗體發現和優化，為全球製藥行業日益增長的發現需求提供了一種高效且可定製的端到端解決方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.024639},{"month":2,"riseRate":0.2,"avgChangeRate":-0.040779},{"month":3,"riseRate":0.4,"avgChangeRate":-0.013448},{"month":4,"riseRate":0,"avgChangeRate":-0.131109},{"month":5,"riseRate":0.25,"avgChangeRate":-0.052576},{"month":6,"riseRate":0.25,"avgChangeRate":-0.101946},{"month":7,"riseRate":1,"avgChangeRate":0.359887},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002821},{"month":9,"riseRate":0,"avgChangeRate":-0.115532},{"month":10,"riseRate":0.4,"avgChangeRate":0.027488},{"month":11,"riseRate":0.2,"avgChangeRate":-0.198095},{"month":12,"riseRate":0.8,"avgChangeRate":0.286403}],"exchange":"NASDAQ","name":"OMNIAB INC C/WTS (TO PUR COM)","nameEN":"OMNIAB INC C/WTS (TO PUR COM)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OABIW\",market:\"US\",,,undefined,":null}}